Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $116.17.
Several equities analysts have recently commented on the company. Credit Suisse Group boosted their price objective on United Therapeutics from $113.00 to $121.00 and gave the company an “outperform” rating in a research report on Thursday. Zacks Investment Research downgraded United Therapeutics from a “hold” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research report on Thursday, January 2nd. ValuEngine downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 4th. Wedbush restated a “buy” rating and issued a $237.00 price objective on shares of United Therapeutics in a research report on Monday, February 3rd. Finally, Bank of America started coverage on United Therapeutics in a research report on Tuesday, December 3rd. They issued an “underperform” rating and a $80.00 target price on the stock.
Several large investors have recently bought and sold shares of UTHR. BBVA USA Bancshares Inc. bought a new stake in United Therapeutics during the fourth quarter worth approximately $28,000. Parallel Advisors LLC increased its stake in United Therapeutics by 356.6% during the fourth quarter. Parallel Advisors LLC now owns 347 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 271 shares during the last quarter. Chevy Chase Trust Holdings Inc. bought a new stake in United Therapeutics during the fourth quarter worth approximately $31,000. NWK Group Inc. bought a new stake in United Therapeutics during the fourth quarter worth approximately $35,000. Finally, Quadrant Capital Group LLC increased its stake in United Therapeutics by 61.2% during the third quarter. Quadrant Capital Group LLC now owns 661 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 251 shares during the last quarter. Institutional investors own 93.26% of the company’s stock.
Shares of United Therapeutics stock traded up $0.12 during trading hours on Friday, hitting $104.11. The company’s stock had a trading volume of 13,611 shares, compared to its average volume of 460,490. The business has a 50 day moving average price of $92.51 and a two-hundred day moving average price of $87.07. United Therapeutics has a 12-month low of $74.31 and a 12-month high of $128.94. The company has a market cap of $4.56 billion, a PE ratio of -47.98, a PEG ratio of -1.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.91 and a current ratio of 4.11.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: What is the Beige Book?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.